Table 8 Incidence rates of the different intrinsic subtypes in comparison with other studies.
From: Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy
Total number of patients | Luminal A (%) | Luminal B (%) HER2+ | Luminal B (%) Her2− | HER2+ (%) | Triple negative (%) | |
|---|---|---|---|---|---|---|
2003–2009 | 78 | 29.5 | 16.7 | 19.2 | 16.7 | 17.9 |
2010–2017 | 262 | 19.9 | 22.1 | 11.1 | 17.9 | 29.0 |
2003–2017 | 340 | 22.1 | 20.9 | 12.9 | 17.6 | 26.5 |
German 20132 | 1604 | 35.6 | 17.5 | 13.1 | 11.1 | 22.5 |
German 202013 | 4193 | 39.0 | 17.9 | 8.5 | 12.8 | 21.7 |
CTNeoBC 201425 | 5694 | 34.8 | 19.1 | 11.1 | 14.7 | 20.3 |
EORTC 201314 | 1289 | 40 | 18.4 | 11.9 | 9.9 | 19.8 |
